title: Short-course of oral miltefosine for treatment of visceral leishmaniasis.
abstract: A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.
authors.affiliation: The Kala-Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India. shyams@nde.vsnl.net.in
authors.forename: S
authors.initials: S
authors.lastname: Sundar
authors.forename: A
authors.initials: A
authors.lastname: Makharia
authors.forename: D K
authors.initials: DK
authors.lastname: More
authors.forename: G
authors.initials: G
authors.lastname: Agrawal
authors.forename: A
authors.initials: A
authors.lastname: Voss
authors.forename: C
authors.initials: C
authors.lastname: Fischer
authors.forename: P
authors.initials: P
authors.lastname: Bachmann
authors.forename: H W
authors.initials: HW
authors.lastname: Murray
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine